Clayton Dehn

Clayton Dehn has a rich and diverse work experience in the field of clinical pharmacology services and metabolic research. Clayton currently holds the position of Vice President of Clinical Pharmacology Services at Evolution Research Group. Prior to this, Clayton worked as a Consultant at the Foundation for the National Institutes of Health. From 2018 to 2020, they served as Vice President of Clinical Pharmacology Services at High Point Clinical Trials Center. Clayton also held the role of Senior Vice President at Clinical Trials of Texas, Inc. Clayton's entrepreneurial side was exhibited through their co-founding and CEO role at Umbrella Corporation, where they focused on developing new therapies for metabolic disorders. Moreover, they served as a Commissioner at the Arizona Biomedical Research Commission. Clayton has held various executive roles at organizations such as Celerion, ICON plc, and Cetero Research, where they gained expertise in metabolic diseases and glucose clamp services.

Clayton Dehn obtained a Master of Science degree in Physiology from Texas Tech University in 2003.